Proactive Investors Interview – Algernon Pharmaceuticals Establishes Optimum Treatment Period for DMT
Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share news that the company has established the optimum peak stimulation period of 6 hours for neuron outgrowth by AP-188 or DMT. The increased growth was achieved with a sub-hallucinogenic dose.
Mr. Moreau also explains that this current data set is from the second part of their in-vitro experiment designed to focus on the duration of infusion needed to achieve maximal cortical neuron outgrowth. The data showed that an increase in growth of over 40% was observed in the group treated for 6 hours with 30 nM DMT.
